2 terminated, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow Andrew Ko: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma PEGPH20, Gemcitabine, Nab-paclitaxel - Adenocarcinoma | Phase 2 | Terminated | Andrew Ko | 3 | 2015-07-14 | 2020-01-02 |
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma FOLFIRINOX, IPI-926 - Pancreatic Cancer, Adenocarcinoma | Phase 1 | Completed | Andrew Ko | 15 | 2011-08-23 | 2017-08-08 |
| Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer S-1, gemcitabine hydrochloride - Pancreatic Cancer | Phase 2 | Terminated | Andrew Ko | 21 | 2007-01-22 | 2020-09-18 |
Adenocarcinoma (2) · Pancreatic Neoplasms (2) · Neoplasms (1)
Gemcitabine (2) · 130-nm albumin-bound paclitaxel (1) · Fluorouracil (1) · IPI-926 (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · PEGPH20 (1) · S 1 (combination) (1) · folfirinox (1) · titanium silicide (1)
United States (3)